Ropinirole for restless legs syndrome
Identifieur interne : 003462 ( Istex/Corpus ); précédent : 003461; suivant : 003463Ropinirole for restless legs syndrome
Auteurs : William OndoSource :
- Movement Disorders [ 0885-3185 ] ; 1999-01.
English descriptors
Abstract
Restless legs syndrome (RLS) is a common and underdiagnosed condition that results in a desire to move the extremities often associated with paresthesia/dysesthesia, motor restlessness, worsening of symptoms at rest with at least temporary relief by activity, and worsening of symptoms in the evening or night. We tested the new dopamine agonist ropinirole in 16 patients with RLS in an open‐label trial. The mean daily dose was 2.8 ± 2.3 mg (range, 0.5–12.0). The 13 patients who completed the study reported a 58.7% improvement (p = 1.08 × 10−8) as judged by the abbreviated International Restless Legs Study Group questionnaire. Three patients discontinued the medication secondary to adverse events (rash and nervousness) and other extenuating circumstances. These encouraging preliminary results justify larger and more controlled trials of ropinirole in patients with RLS.
Url:
DOI: 10.1002/1531-8257(199901)14:1<138::AID-MDS1023>3.0.CO;2-A
Links to Exploration step
ISTEX:8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ropinirole for restless legs syndrome</title><author><name sortKey="Ondo, William" sort="Ondo, William" uniqKey="Ondo W" first="William" last="Ondo">William Ondo</name><affiliation><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1002/1531-8257(199901)14:1<138::AID-MDS1023>3.0.CO;2-A</idno><idno type="url">https://api.istex.fr/document/8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003462</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ropinirole for restless legs syndrome</title><author><name sortKey="Ondo, William" sort="Ondo, William" uniqKey="Ondo W" first="William" last="Ondo">William Ondo</name><affiliation><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-01">1999-01</date><biblScope unit="vol">14</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="138">138</biblScope><biblScope unit="page" to="140">140</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053</idno><idno type="DOI">10.1002/1531-8257(199901)14:1<138::AID-MDS1023>3.0.CO;2-A</idno><idno type="ArticleID">MDS1023</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine agonists</term><term>Restless legs syndrome</term><term>Ropinirole</term><term>Sleep disorders</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Restless legs syndrome (RLS) is a common and underdiagnosed condition that results in a desire to move the extremities often associated with paresthesia/dysesthesia, motor restlessness, worsening of symptoms at rest with at least temporary relief by activity, and worsening of symptoms in the evening or night. We tested the new dopamine agonist ropinirole in 16 patients with RLS in an open‐label trial. The mean daily dose was 2.8 ± 2.3 mg (range, 0.5–12.0). The 13 patients who completed the study reported a 58.7% improvement (p = 1.08 × 10−8) as judged by the abbreviated International Restless Legs Study Group questionnaire. Three patients discontinued the medication secondary to adverse events (rash and nervousness) and other extenuating circumstances. These encouraging preliminary results justify larger and more controlled trials of ropinirole in patients with RLS.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>William Ondo MD</name><affiliations><json:string>Department of Neurology, Baylor College of Medicine, Houston, Texas, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Restless legs syndrome</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Ropinirole</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Dopamine agonists</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Sleep disorders</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Restless legs syndrome (RLS) is a common and underdiagnosed condition that results in a desire to move the extremities often associated with paresthesia/dysesthesia, motor restlessness, worsening of symptoms at rest with at least temporary relief by activity, and worsening of symptoms in the evening or night. We tested the new dopamine agonist ropinirole in 16 patients with RLS in an open‐label trial. The mean daily dose was 2.8 ± 2.3 mg (range, 0.5–12.0). The 13 patients who completed the study reported a 58.7% improvement (p = 1.08 × 10−8) as judged by the abbreviated International Restless Legs Study Group questionnaire. Three patients discontinued the medication secondary to adverse events (rash and nervousness) and other extenuating circumstances. These encouraging preliminary results justify larger and more controlled trials of ropinirole in patients with RLS.</abstract><qualityIndicators><score>3.277</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>878</abstractCharCount><pdfWordCount>1693</pdfWordCount><pdfCharCount>11486</pdfCharCount><pdfPageCount>3</pdfPageCount><abstractWordCount>132</abstractWordCount></qualityIndicators><title>Ropinirole for restless legs syndrome</title><genre><json:string>Serial article</json:string></genre><host><volume>14</volume><pages><total>3</total><last>140</last><first>138</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1999</publicationDate><copyrightDate>1999</copyrightDate><doi><json:string>10.1002/1531-8257(199901)14:1>138::AID-MDS1023>3.0.CO;2-A</json:string></doi><id>8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Ropinirole for restless legs syndrome</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><p>John Wiley & Sons, Inc.</p></availability><date>1999</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Ropinirole for restless legs syndrome</title><author><persName><forename type="first">William</forename><surname>Ondo</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: 6550 Fannin Dr, Suite 1801, Houston, TX 77030, U.S.A.</p></note><affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, U.S.A.</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-01"></date><biblScope unit="vol">14</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="138">138</biblScope><biblScope unit="page" to="140">140</biblScope></imprint></monogr><idno type="istex">8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053</idno><idno type="DOI">10.1002/1531-8257(199901)14:1<138::AID-MDS1023>3.0.CO;2-A</idno><idno type="ArticleID">MDS1023</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1999</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Restless legs syndrome (RLS) is a common and underdiagnosed condition that results in a desire to move the extremities often associated with paresthesia/dysesthesia, motor restlessness, worsening of symptoms at rest with at least temporary relief by activity, and worsening of symptoms in the evening or night. We tested the new dopamine agonist ropinirole in 16 patients with RLS in an open‐label trial. The mean daily dose was 2.8 ± 2.3 mg (range, 0.5–12.0). The 13 patients who completed the study reported a 58.7% improvement (p = 1.08 × 10−8) as judged by the abbreviated International Restless Legs Study Group questionnaire. Three patients discontinued the medication secondary to adverse events (rash and nervousness) and other extenuating circumstances. These encouraging preliminary results justify larger and more controlled trials of ropinirole in patients with RLS.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Restless legs syndrome</term></item><item><term>Ropinirole</term></item><item><term>Dopamine agonists</term></item><item><term>Sleep disorders</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1998-05-20">Received</change><change when="1998-07-31">Registration</change><change when="1999-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/1531-8257(199901)14:1<>1.0.CO;2-W</doi><numberingGroup><numbering type="journalVolume" number="14">14</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="1999-01">January 1999</coverDate></publicationMeta><publicationMeta level="unit" type="shortCommunication" position="23" status="forIssue"><doi origin="wiley" registered="yes">10.1002/1531-8257(199901)14:1<138::AID-MDS1023>3.0.CO;2-A</doi><idGroup><id type="unit" value="MDS1023"></id></idGroup><countGroup><count type="pageTotal" number="3"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 1999 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="1998-05-20"></event><event type="manuscriptRevised" date="1998-07-28"></event><event type="manuscriptAccepted" date="1998-07-31"></event><event type="firstOnline" date="2001-01-22"></event><event type="publishedOnlineFinalForm" date="2001-01-22"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-04"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">138</numbering><numbering type="pageLast">140</numbering></numberingGroup><correspondenceTo>6550 Fannin Dr, Suite 1801, Houston, TX 77030, U.S.A.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS1023.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="10"></count><count type="wordTotal" number="1635"></count></countGroup><titleGroup><title type="main" xml:lang="en">Ropinirole for restless legs syndrome</title><title type="short" xml:lang="en">Ropinirole for Restless Legs Syndrome</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>William</givenNames><familyName>Ondo</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Restless legs syndrome</keyword><keyword xml:id="kwd2">Ropinirole</keyword><keyword xml:id="kwd3">Dopamine agonists</keyword><keyword xml:id="kwd4">Sleep disorders</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Restless legs syndrome (RLS) is a common and underdiagnosed condition that results in a desire to move the extremities often associated with paresthesia/dysesthesia, motor restlessness, worsening of symptoms at rest with at least temporary relief by activity, and worsening of symptoms in the evening or night. We tested the new dopamine agonist ropinirole in 16 patients with RLS in an open‐label trial. The mean daily dose was 2.8 ± 2.3 mg (range, 0.5–12.0). The 13 patients who completed the study reported a 58.7% improvement (p = 1.08 × 10<sup>−8</sup>) as judged by the abbreviated International Restless Legs Study Group questionnaire. Three patients discontinued the medication secondary to adverse events (rash and nervousness) and other extenuating circumstances. These encouraging preliminary results justify larger and more controlled trials of ropinirole in patients with RLS.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Ropinirole for restless legs syndrome</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Ropinirole for Restless Legs Syndrome</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Ropinirole for restless legs syndrome</title></titleInfo><name type="personal"><namePart type="given">William</namePart><namePart type="family">Ondo</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, U.S.A.</affiliation><description>Correspondence: 6550 Fannin Dr, Suite 1801, Houston, TX 77030, U.S.A.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">shortCommunication</genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">1999-01</dateIssued><dateCaptured encoding="w3cdtf">1998-05-20</dateCaptured><dateValid encoding="w3cdtf">1998-07-31</dateValid><copyrightDate encoding="w3cdtf">1999</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">1</extent><extent unit="references">10</extent><extent unit="words">1635</extent></physicalDescription><abstract lang="en">Restless legs syndrome (RLS) is a common and underdiagnosed condition that results in a desire to move the extremities often associated with paresthesia/dysesthesia, motor restlessness, worsening of symptoms at rest with at least temporary relief by activity, and worsening of symptoms in the evening or night. We tested the new dopamine agonist ropinirole in 16 patients with RLS in an open‐label trial. The mean daily dose was 2.8 ± 2.3 mg (range, 0.5–12.0). The 13 patients who completed the study reported a 58.7% improvement (p = 1.08 × 10−8) as judged by the abbreviated International Restless Legs Study Group questionnaire. Three patients discontinued the medication secondary to adverse events (rash and nervousness) and other extenuating circumstances. These encouraging preliminary results justify larger and more controlled trials of ropinirole in patients with RLS.</abstract><subject lang="en"><genre>Keywords</genre><topic>Restless legs syndrome</topic><topic>Ropinirole</topic><topic>Dopamine agonists</topic><topic>Sleep disorders</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>138</start><end>140</end><total>3</total></extent></part></relatedItem><identifier type="istex">8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053</identifier><identifier type="DOI">10.1002/1531-8257(199901)14:1<138::AID-MDS1023>3.0.CO;2-A</identifier><identifier type="ArticleID">MDS1023</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1999 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>John Wiley & Sons, Inc.</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003462 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003462 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053
|texte= Ropinirole for restless legs syndrome
}}
| This area was generated with Dilib version V0.6.23. |  |